TY - JOUR T1 - Criteria for PF-ILD in a cohort of patients with chronic hypersensitivity pneumonitis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.3538 VL - 56 IS - suppl 64 SP - 3538 AU - Eduarda Salomé Soares Seixas AU - Paula Serra AU - Margarida Ferreira AU - Renata Aguiar AU - Pedro Gonçalo Ferreira Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/3538.abstract N2 - Introduction: The INBUILD trial has shown that antifibrotic therapy could have a role in fibrosing Interstitial Lung Diseases(ILD) other than idiopathic pulmonary fibrosis, enabling a reduction of lung function declineObjectives: Investigating the proportion of patients with chronic hypersensitivity pneumonitis(cHP) which fulfilled progression criteria used in INBUILD trial(last 24 months)Methods: Retrospective study with record of cHP patient´s clinical dataResults: We identified 83 patients with HP, 63 of them with cHP. This subgroup had a mean age of 69,3 years and a female predominance (55,6%). The most common causal antigen was avian (57,1%). Mean baseline FVC was 77,6% and the last was 73,3%. At baseline most presented with dyspnea grade 2 (55,6%). Around 68,3% had chronic cough. A UIP/UIP-like pattern was present in 46,0% of patients.Of cHP patients 33,3%(n=21) achieved criteria for progressive-fibrosing (PF)-ILD:66,7% by a relative decline≥10% FVC, 9,5% by a relative decline of 5-9%FVC and worsening symptoms/progression of fibrosis on HRCT and 23,8% by worsening of respiratory symptoms and increased extent of fibrosis. Of these patients, 95,2% were being treated with corticosteroids some combined with mycophenolate mofetil(55%) or azathioprine(20%). Among the patients with PF-ILD criteria 61,9% presented a UIP/UIP-like pattern.Conclusion: A subgroup of cHP patients doesn´t respond to immunosuppressive therapy. This form of HP has recently gained attention in clinical trials with antifibrotic therapy. This study shows that one third of our cHP patients could be considered to have PF-ILD. This subgroup can be considered candidates for antifibrotic with a perspective of disease stabilization.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3538.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -